Factors Associated with Relative Rates of Antibiotic Resistance in Pseudomonas aeruginosa Isolates Tested in Clinical Laboratories in the United States from 1999 to 2002

ABSTRACT For the period from 1999 to 2002 in the United States, the in vitro susceptibilities of 52,637 Pseudomonas aeruginosa isolates to 10 antimicrobial agents were evaluated. The isolates were from 29 laboratories, 11 of which participated in The Surveillance Network for four consecutive years. Isolates were collected from adult patients (≥18 years of age) in intensive care units (ICU), non-ICU inpatients, nursing home patients, and outpatients; data were analyzed to evaluate factors, such as year of isolation, patient age group, isolate specimen source, and patient type (hospitalized patients [ICU, non-ICU, or nursing home] or outpatients). Rates of resistance for the 4-year period were highest for isolates from patients in ICU and 18- to 39-year-old patients and for isolates from the lower respiratory tract. Resistance decreased with age. Resistance was lowest in isolates from outpatients, in isolates from ≥70-year-old patients, and from specimens from the upper respiratory tract. Multidrug resistance (MDR) (resistance to three or more antimicrobial agents) accounted for 24.9% of all isolates. The MDR rate was highest in isolates from patients in nursing homes (29.9%) and ICU (29.5%).

[1]  Ronald N. Jones,et al.  Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). , 2002, Diagnostic microbiology and infectious disease.

[2]  D. Livermore,et al.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  A. Evangelista,et al.  Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network. , 2002, International journal of antimicrobial agents.

[4]  M. Pfaller,et al.  Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). , 2001, Diagnostic microbiology and infectious disease.

[5]  Ronald N. Jones,et al.  Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  D. Livermore Of Pseudomonas, porins, pumps and carbapenems. , 2001, The Journal of antimicrobial chemotherapy.

[7]  J. Karlowsky,et al.  Evaluation of Current Activities of Fluoroquinolones against Gram-Negative Bacilli Using Centralized In Vitro Testing and Electronic Surveillance , 2001, Antimicrobial Agents and Chemotherapy.

[8]  Albert Balows,et al.  Manual of Clinical Microbiology, 7th ed. , 2000 .

[9]  M. Pfaller,et al.  Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  M. Marsilio,et al.  Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database--USA. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Y. Carmeli,et al.  Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. , 1999, Archives of internal medicine.

[12]  Y. Carmeli,et al.  Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  A. Levin,et al.  Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Ronald N. Jones,et al.  Bacterial Pathogens Isolated from Patients with Bloodstream Infection: Frequencies of Occurrence and Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997) , 1998, Antimicrobial Agents and Chemotherapy.

[15]  J. Chastre,et al.  Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .